TAmiRNA RNA analysis speed and efficiency boosted by Illumina technology
Biotech and diagnostic innovator TAmiRNA has received a boost to its NextGen Sequencing (NGS) capabilities with the arrival of a leading-edge Illumina NextSeq 2000 machine.
The use of the new system will allow TAmiRNA to generate NGS analysis of microRNA and miND® spike-ins faster and more accurately than ever before with consequent reductions in delivery time of results to clients.
Faster turnaround
The acquisition of the Illumina platform has also enabled TAmiRNA to conduct all its analysis in-house, ending its dependence on external laboratories with long queues, further reducing project turnover times.
The Illumina NextSeq 2000 is capable of up to 1.8 billion single-end reads per run, and will be flexibly integrated in the various RNA-seq workflows that TAmiRNA is using in their services and for their own R&D of diagnostics solutions based on (mi)RNA biomarkers.
Reducing project costs
For TAmiRNA clients, the advent of Illumina automated sequencing will mean enhanced speed and efficiency of sequencing and therefore lower overall service project costs and turnaround times. Other benefits include improvements to all NGS workflows and enhanced flexibility in being able to accommodate service projects of all scales with different flow cell types.
TAmiRNA co-founder and CEO Dr Matthias Hackl commented: “TAmiRNA is constantly working to improve our CRO service offerings with new and optimized workflows. This new state-of-the-art equipment is highly significant in helping us reduce our TAT turnaround times and reduce project costs while maintaining or even enhancing quality.”
About TAmiRNA
TAmiRNA specializes in technologies for profiling levels of blood-circulating miRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for drug development, early diagnosis, and prognosis of disease, and as companion diagnostic tests to support treatment decisions. Through its CRO business, TAmiRNA enables clients from academic to private sectors to perform high-quality biomarker and drug discovery research.
TAmiRNA is among Europe´s first companies that have CE-marked a microRNA-based test – hepatomiR® – which is intended for the diagnosis of liver function in liver cancer patients.
For its work on circulating microRNAs in bone disease, TAmiRNA is receiving funding from the European Union’s Horizon 2020 research and innovation program under the MARIE SKŁODOWSKA-CURIE grant agreement no. 860898. For TAmiRNA´s work on novel drug safety biomarkers, TAmiRNA receives funding from the Innovative Medicines Initiative 2 Joint Undertaking “TransBioLine” under grant agreement No. 821283. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. For its work on senescence-associated biomarkers, TAmiRNA is receiving funding from Eureka-Eurostars grant Ab-SENS. For its work on novel liver function biomarkers, TAmiRNA is receiving funding from the Vienna Business Agency as well as FFG.
More information available at: www.tamirna.com
Resources
Click on TAmiRNA MiND Next Generation Sequencing for further information.